{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for methyl root_codes_WIKIPEDIA in WIKIPEDIA (approximate match)
Status:
Possibly Marketed Outside US
Source:
21 CFR 333E
(2021)
Source URL:
First approved in 2005
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Possibly Marketed Outside US
Source:
NDA021488
(2002)
Source URL:
First approved in 2002
Source:
21 CFR 333D
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Methyl pyrrolidone (or N-methyl pyrrolidone or NMP) is a small molecule acetyl‐lysine mimetic compound with potent immunomodulatory and direct anti‐myeloma activity. NMP is nontoxic, stable and already in use as a solvent in biomedical applications. This compound is under investigation in clinical trial phase I for the treatment of multiple myeloma. The study will evaluate if the NMP can be safely administered to humans at doses, which induce measurable immunological and anti-tumor effects in patients with myeloma. In addition, NMP could be useful for bone fracture repairing. NMP has shown a protective role in osteoblast differentiation in response to hypoxia, and such protection was through inhibiting the NF-κB signaling. Experiments on rodents have revealed that the compound had a remarkable anti-osteoporotic ability preserving activity in the pulp-dentine complex and preventing jawbone loss. These effects made NMP a promising candidate for the preservation of the activity of the pulp-dentin complex and jawbone thickness in post-menopausal females.
Status:
Possibly Marketed Outside US
Source:
M017
(2000)
Source URL:
First approved in 2000
Source:
M017
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2004)
Source URL:
First approved in 2000
Source:
ANDA075289
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Source:
M017
(2011)
Source URL:
First approved in 1998
Source:
NDA205394
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Methyl ethyl ketone (butanone) is an industrial solvent produced on a large scale. It is used in surface coatings, adhesives, printing inks, chemical intermediates, magnetic tapes, and lube oil dewaxing agents. Methyl ethyl ketone has a fruity odor similar to acetone. It is used as a flavor/fragrance agent in pharmaceuticals and cosmetics.
Status:
Possibly Marketed Outside US
Source:
ANDA078730
(1995)
Source URL:
First approved in 1995
Source:
ANDA078730
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
First approved in 1993
Source:
21 CFR 352
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Octisalate used as an ingredient in sunscreens and cosmetics. Maximum FDA-approved concentration - 5%. Range of protection - UVB. Might develop contact allergic dermatitis
Status:
Possibly Marketed Outside US
Source:
21 CFR 333A
(1989)
Source URL:
First approved in 1989
Source:
21 CFR 333A
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Cupric salicylate is an anti-inflammatory agent which was used as pain relief for patients with osteoarthritis, rheumatoid and other degenerative diseases (as a copper-salicylate complex). The preparation seem to be discontinued for now.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ACHIRAL)
Imidazole salicylate (also known as ITF-182), a nonsteroidal anti-inflammatory drug (NSAID) that inhibits Tromboxane A2 synthesis, without interfering with cyclo-oxygenase pathway and possesses the limited inhibitory effects on prostaglandin synthesis. Imidazole salicylate can be used for the treatment of osteoarthrosis and musculoskeletal trauma. In addition, it can be given to patients with decompensated cirrhosis without risk of inhibiting kidney prostaglandin synthesis. Imidazole salicylate was characterized by good gastric tolerability and could be assigned for treatment of rheumatic diseases in the elderly. The drug also can be safely used in aspirin-sensitive patients.
